Physician profile
Mei Hui
NPI 1760695621
$2,626.12
in general payments reported to CMS, 2019-2025
25 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $171 · 2021: $110 · 2022: $287 · 2023: $341 · 2024: $400 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,186.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $520.04 | 2019-2025 | Breztri, Farxiga |
| Amgen INC. | $352.99 | 2019-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $266.12 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $260.81 | 2019-2025 | |
| Novo Nordisk INC | $245.94 | 2019-2025 | Ozempic, Rybelsus |
| Supernus Pharmaceuticals, INC. | $178.32 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $115.53 | 2019-2022 | |
| Exact Sciences Corporation | $78.93 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $71.28 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Astellas Pharma US INC | $66.50 | 2025 | Veozah |
| Abbvie INC. | $61.07 | 2024-2025 | |
| Lilly USA, LLC | $57.55 | 2019-2024 | Mounjaro |
| Abbott Laboratories | $53.92 | 2022-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.81 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $43.17 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $42.45 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.61 | 2019-2025 | Xifaxan |
| Dexcom, INC. | $27.53 | 2024 | Dexcom G6 Transmitter |
| Medtronic USA, INC. | $20.76 | 2019 | |
| Insulet Corporation | $19.12 | 2025 | Omnipod |
| Medtronic, INC. | $15.02 | 2022 | |
| Dynavax Technologies Corporation | $14.83 | 2024 | Heplisav-B |
| Ardelyx, INC. | $13.66 | 2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $13.27 | 2019 | |
| Genentech USA, INC. | $12.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mei Hui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.